// App-Quantinova.ai

1829 : Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study

Researchers

Presenter

  • Lindsay Helget

Principal Investigators

  • Anne Davis-Karim

  • James O'Dell

  • Ted Mikuls

  • Jeff Newcomb

  • Maria Androsenko

  • Mary Brophy

  • Bryant England

  • Ryan Ferguson

  • Michael Pillinger

  • Tuhina Neogi

  • Hongsheng Wu

  • Paul Palevsky

Medical Centers

  • University of Nebraska Medical Center, Omaha, NE

  • VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM

  • Division of Radiology, University of Nebraska Medical Center, Omaha, NE

  • VA Boston Cooperative Studies Program Coordinating Center, Boston, MA

  • Icahn School of Medicine, New York, NY

  • Tufts University School of Medicine, Boston, MA

  • University of Pittsburgh, School of Medicine, Pittsburgh, PA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Autoimmune (AI)

Disease

  • Chronic kidney disease

  • Gout

Biomarkers

  • N/A

Drug/Treatment

  • Allopurinol

  • Febuxostat

  • Adenuric

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved